Peptide Therapy in 2026: What Beverly Hills Patients Need to Know About the Science, the Access, and the Non-Negotiable Role of Physician Supervision

Peptides have moved from the edges of integrative medicine to the center of the longevity and optimization conversation — and in 2026, the conversation has shifted significantly. A combination of clinical validation, a changing regulatory environment, and the enormous credibility transfer from GLP-1 drugs like semaglutide and tirzepatide — themselves peptides — has brought physician-supervised peptide therapy into the mainstream in a way that makes it genuinely worth understanding, even for patients who have been skeptical of wellness trends.

At My Concierge MD in Beverly Hills, Dr. David Nazarian, a board-certified Internal Medicine physician, has been monitoring this evolution closely. For patients who want to understand what peptide therapy actually involves, what the current evidence says, and why the source and supervision of that therapy matters enormously, this guide covers what the field looks like right now.

What Peptides Are — and Why 2026 Is a Pivotal Year

Peptides are short chains of amino acids — the building blocks of proteins — that act as biological signaling molecules in the body. Every peptide has a specific receptor target and a specific downstream effect: stimulating growth hormone release, accelerating tissue repair, modulating inflammation, influencing metabolic rate, or communicating between organ systems. Unlike exogenous hormones, which replace what the body produces, many therapeutic peptides work by stimulating or restoring the body’s own biological processes.

The current surge in peptide interest is not simply hype. Three convergent forces are driving it. First, the clinical success of GLP-1 peptide drugs — semaglutide and tirzepatide — in producing weight loss outcomes more robust than anything previously recorded in pharmaceutical trials has lent scientific credibility to the broader peptide category. If peptides can produce that level of validated clinical impact in one domain, the argument for investigating them across others becomes substantially stronger. Second, the research literature has accelerated dramatically: BPC-157 alone generated more than 180 PubMed-indexed publications in 2025, up from 45 in 2020. Third, the regulatory environment has shifted. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 peptides previously placed on the FDA’s Category 2 restricted list — which had effectively ended licensed compounding pharmacies’ ability to dispense them — are expected to return to Category 1 status, restoring the legal pathway for physician-prescribed compounded peptide therapy. For patients and physicians who had access to these compounds through legitimate clinical channels and lost it in 2023, this is a meaningful change.

The Peptides With the Strongest Evidence Profiles

Within the broad category of therapeutic peptides, several specific compounds have accumulated meaningful evidence in human or high-quality preclinical research and are frequently incorporated into physician-supervised protocols.

CJC-1295 / Ipamorelin (Growth Hormone Secretagogue Stack): This pairing is among the most established protocols in physician-supervised peptide therapy. CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to secrete more growth hormone. Ipamorelin is a selective ghrelin-receptor agonist — a growth hormone secretagogue — that amplifies and sharpens the GH pulses CJC-1295 initiates while producing minimal effects on cortisol or prolactin, a profile that distinguishes it favorably from earlier secretagogues. Together, they work synergistically to produce sustained, physiologic elevation of growth hormone and IGF-1.

The clinical applications in physician-supervised contexts include improved body composition, enhanced lean mass preservation, improved sleep quality (GH is released primarily during deep sleep and is essential for tissue repair), accelerated recovery from exertion and injury, and metabolic support. For patients in their 40s and 50s whose natural growth hormone production has declined significantly from its peak — a normal physiological change that accelerates after 30 — restoring more physiologic GH patterns produces effects that patients often describe as the most noticeable change they experience in any optimization protocol.

Sermorelin: A GHRH analog similar in mechanism to CJC-1295 but shorter-acting and representing one of the longest-used peptides in clinical practice. Sermorelin has FDA approval history for pediatric growth hormone deficiency, giving it a human safety profile that many newer peptides lack. It is frequently used as a gentler entry point for GH secretagogue therapy or as a stand-alone protocol for patients seeking sleep quality and recovery improvement with a well-characterized safety profile.

BPC-157 (Body Protection Compound): BPC-157 is a synthetic pentadecapeptide derived from a protein found in human gastric juice and has generated substantial preclinical research across multiple tissue types. Its proposed mechanisms involve upregulating growth factor signaling relevant to tissue repair, modulating the nitric oxide system, and influencing the gut-brain axis. The research literature — now exceeding 180 publications indexed in 2025 — documents effects on tendon and muscle healing, gastrointestinal protection, wound repair, and neurological resilience across animal models. Human clinical data remains limited and some findings require replication with appropriate controls, which is exactly why its administration in the context of physician supervision — with baseline evaluation, clear goals, and outcome monitoring — is distinctly preferable to self-administration based on forum recommendations.

GHK-Cu (Copper Tripeptide): One of the most extensively studied peptides in regenerative medicine, GHK-Cu is a naturally occurring copper-binding tripeptide with documented roles in wound healing, collagen synthesis, and tissue remodeling. Three new randomized controlled trials were initiated in 2025. Its search volume has grown more than 1,000% year-over-year, driven in part by applications in hair regrowth, skin regeneration, and systemic anti-inflammatory effects. It is among the peptides with the most directly translatable human evidence and the most accessible safety profile.

Why Physician Supervision Is Non-Negotiable

The most important thing Beverly Hills patients should understand about peptide therapy in 2026 is that the quality of the clinical supervision surrounding it determines the safety and the value of the intervention far more than the peptides themselves.

The gray market for peptide compounds — vials sold as “research chemicals” online for a fraction of clinical pricing — represents a genuine and underappreciated risk. Independent laboratory testing of peptide vials sourced from online vendors has documented underdosing, contamination, incorrect compounds, and sterility failures. Subcutaneous injection of a compound with an unknown sterility profile carries real infection risk. Administration of a peptide without baseline laboratory evaluation, without an understanding of the patient’s current hormonal status, and without monitoring of downstream markers is both clinically unsound and capable of producing outcomes no one intended.

At My Concierge MD, peptide therapy is integrated into a comprehensive evaluation that includes the baseline laboratory work — IGF-1, growth hormone, metabolic markers, hormonal status, and inflammatory biomarkers — needed to determine appropriate candidacy, calibrate protocols to individual physiology, and monitor outcomes over time. Dr. Nazarian’s board certification in Internal Medicine and his expertise in hormone optimization provide the clinical framework that makes peptide protocols genuinely personalized rather than generically applied.

The 24/7 direct physician access that is foundational to the My Concierge MD model also means that questions, side effect concerns, or protocol adjustments that arise between scheduled appointments don’t require waiting for an available slot in an overloaded practice. For therapies where titration and monitoring are central to safe and effective use, this access is not a luxury — it is a clinical requirement.

Who Is a Candidate for Peptide Therapy

The patients who benefit most from physician-supervised peptide protocols are generally adults in their mid-30s and beyond who are experiencing the physiological changes associated with declining growth hormone — reduced sleep quality, impaired recovery from training or activity, changes in body composition despite consistent habits, lower energy and drive — and who want to address these changes through a mechanism that works with their biology rather than replacing it wholesale.

Peptide therapy is also highly relevant for patients managing recovery from injury, surgery, or prolonged illness; patients seeking to extend the productive years of physical capability; and patients who have already optimized the basics — sleep, nutrition, exercise, stress management — and are looking for what precision medicine can add at the next level.
Patients with active malignancy, uncontrolled diabetes, or certain hormonal conditions may not be appropriate candidates, which is precisely why baseline evaluation precedes any protocol at My Concierge MD.

Schedule Your Peptide Therapy Consultation at My Concierge MD

Dr. David Nazarian and the My Concierge MD team welcome consultations for peptide therapy from patients throughout Beverly Hills and greater Los Angeles, with house call and hotel visit options for patients who prefer care at their location. Our office is located at 9301 Wilshire Boulevard, Suite 405A, in Beverly Hills. Call (310) 299-8959 to schedule your consultation. The peptide landscape has changed significantly in 2026 — make sure the guidance you’re receiving has kept up with it.